• Conformetrix Ltd., of Manchester, UK, and AstraZeneca plc, of London, signed a research collaboration agreement allowing AstraZeneca to apply Conformetrix's NMR-based technology across its preclinical therapeutic pipeline to enhance lead discovery and hit identification.